Mogamulizumab induces long‐term immune restoration and reshapes tumour heterogeneity in Sézary syndrome *
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Dermatology"
DOI: 10.1111/bjd.21018
Abstract: Mogamulizumab, an anti‐CCR4 monoclonal antibody, has been shown to increase progression‐free survival in cutaneous T‐cell lymphoma. read more here.
Keywords: long term; immune restoration; induces long; mogamulizumab induces ... See more keywords